Many early-stage compounds are abandoned due to poor biopharmaceutical properties, such as low solubility or low permeability, and many sub-optimized formulations of poorly soluble drugs are rushed through development in the race to be the first to market. As such, there are many opportunities in formulation orreformulation to enhance bioavailability, safety and efficacy, which is where Ascendia has made its mark.

A Decade of Growth

Ascendia quickly outgrew its original 800 square foot labs and moved to the New Jersey Bioscience Center in North Brunswick, NJ, in 2017. Continued growth in services and increasing projects saw Ascendia experiencing rapid growth. Today, it has a 60,000 square foot headquarters, which is home to nearly 100 employees.

Currently, Ascendia has 8 class 100/10,000 sterile GMP manufacturing clean rooms to support pilot studies, Phase I clinical trial materials (CTM), and small commercial manufacturing. It also has 5 class 100,000 non-sterile GMP clean rooms to support up to early Phase II CTM.